SEARCH

SEARCH BY CITATION

References

  • 1
    Barakat MT, Meeran K, Bloom SR. Neuroendocrine tumours. Endocr Relat Cancer. 2004; 11: 1-18.
  • 2
    Bettini R, Boninsegna L, Mantovani W, et al. Prognostic factors at diagnosis and value of WHO classification in a mono-institutional series of 180 non-functioning pancreatic endocrine tumours. Ann Oncol. 2008; 19: 903-908.
  • 3
    Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008; 26: 3063-3072.
  • 4
    Rindi G, Kloppel G, Alhman H, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2006; 449: 395-401.
  • 5
    Rindi G, Kloppel G, Couvelard A, et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2007; 451: 757-762.
  • 6
    Plockinger U, Rindi G, Arnold R, et al. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology. 2004; 80: 394-424.
  • 7
    Moertel CG, Hanley JA, Johnson LA. Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med. 1980; 303: 1189-1194.
  • 8
    Engstrom PF, Lavin PT, Moertel CG, Folsch E, Douglass HO Jr. Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor. J Clin Oncol. 1984; 2: 1255-1259.
  • 9
    Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med. 1992; 326: 519-523.
  • 10
    Sun W, Lipsitz S, Catalano P, Mailliard JA, Haller DG. Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. J Clin Oncol. 2005; 23: 4897-4904.
  • 11
    Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008; 26: 2124-2130.
  • 12
    Yao JC, Phan AT, Chang DZ, et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol. 2008; 26: 4311-4318.
  • 13
    Kulke MH, Lenz HJ, Meropol NJ, et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol. 2008; 26: 3403-3410.
  • 14
    Burris HA III, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997; 15: 2403-2413.
  • 15
    Kulke MH, Kim H, Clark JW, et al. A phase II trial of gemcitabine for metastatic neuroendocrine tumors. Cancer. 2004; 101: 934-939.
  • 16
    de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000; 18: 2938-2947.
  • 17
    Louvet C, Labianca R, Hammel P, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J. Clin Oncol. 2005; 23: 3509-3516.
  • 18
    Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008; 358: 36-46.
  • 19
    Andre T, Tournigand C, Rosmorduc O, et al. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol. 2004; 15: 1339-1343.
  • 20
    Tetzlaff ED, Ajani JA. Oxaliplatin-based chemotherapy for the treatment of a metastatic carcinoid tumor. Int J Gastrointest Cancer. 2005; 36: 55-58.
  • 21
    Bajetta E, Catena L, Procopio G, et al. Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours? Cancer Chemother Pharmacol. 2007; 59: 637-642.
  • 22
    Kunz PL, Kuo T, Kaiser HL, et al. A phase II study of capecitabine, oxaliplatin and bevacizumab for metastatic or unresectable neuroendocrine tumors: preliminary results [abstract]. ASCO Meeting Abstr. 2008; 26: 15502.
  • 23
    Venook AP, Ko AH, Tempero MA, et al. Phase II trial of FOLFOX plus bevacizumab in advanced, progressive neuroendocrine tumors [abstract]. ASCO Meeting Abstr. 2008; 26: 15545.
  • 24
    DeLellis RA, Lloyd RV, Heitz PU, Eng C. World Health Organization Classification of Tumours, Pathology and Genetics of Tumours of Endocrine Organs. Lyon, France: IARC Press; 2004.
  • 25
    Travis WD, Gal AA, Colby TV, Klimstra DS, Falk R, Koss MN. Reproducibility of neuroendocrine lung tumor classification. Hum Pathol. 1998; 29: 272-279.
  • 26
    Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205-216.
  • 27
    Kouvaraki MA, Ajani JA, Hoff P, et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol. 2004; 22: 4762-4771.
  • 28
    Delaunoit T, Ducreux M, Boige V, et al. The doxorubicin-streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma; a judicious option? Eur J Cancer. 2004; 40: 515-520.
  • 29
    Bajetta E, Ferrari L, Procopio G, et al. Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours. Ann Oncol. 2002; 13: 614-621.
  • 30
    Granberg D, Eriksson B, Wilander E, et al. Experience in treatment of metastatic pulmonary carcinoid tumors. Ann Oncol. 2001; 12: 1383-1391.
  • 31
    Wirth LJ, Carter MR, Janne PA, Johnson BE. Outcome of patients with pulmonary carcinoid tumors receiving chemotherapy or chemoradiotherapy. Lung Cancer. 2004; 44: 213-220.
  • 32
    Ansell SM, Pitot HC, Burch PA, Kvols LK, Mahoney MR, Rubin J. A phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors. Cancer. 2001; 91: 1543-1548.
  • 33
    Kulke MH, Kim H, Stuart K, et al. A phase II study of docetaxel in patients with metastatic carcinoid tumors. Cancer Invest. 2004; 22: 353-359.
  • 34
    Ansell SM, Mahoney MR, Green EM, Rubin J. Topotecan in patients with advanced neuroendocrine tumors: a phase II study with significant hematologic toxicity. Am J Clin Oncol. 2004; 27: 232-235.
  • 35
    Ekeblad S, Sundin A, Janson ET, et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res. 2007; 13: 2986-2991.
  • 36
    Kulke MH, Stuart K, Enzinger PC, et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol. 2006; 24: 401-406.
  • 37
    Kulke MH, Stuart K, Earle CC, et al. A phase II study of temozolomide and bevacizumab in patients with advanced neuroendocrine tumors. ASCO Meeting Abstr. 2006; 24: 4044.
  • 38
    Isacoff WH, Moss RA, Pecora AL, Fine RL. Temozolomide/capecitabine therapy for metastatic neuroendocrine tumors of the pancreas. A retrospective review. ASCO Meeting Abstr. 2006; 24: 14023.
  • 39
    Strosberg JR, Choi J, Gardner N, Kvols L. First-line treatment of metastatic pancreatic endocrine carcinoma with capecitabine and temozolomide. ASCO Meeting Abstr. 2008; 26: 4612.
  • 40
    Duran I, Kortmansky J, Singh D, et al. A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer. 2006; 95: 1148-1154.
  • 41
    Hobday TJ, Rubin J, Holen K, et al. MC044h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): a Phase II Consortium (P2C) study. ASCO Meeting Abstr. 2007; 25: 4504.
  • 42
    Yao JC, Phan A, Hoff PM, et al. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol. 2008; 26: 1316-1323.
  • 43
    Kulke M, Lenz HJ, Meropol NJ, et al. A phase 2 study to evaluate the efficacy and safety of SU11248 in patients (pts) with unresectable neuroendocrine tumors (NETs). ASCO Meeting Abstr. 2005; 23: 4008.
  • 44
    Yao JC, Phan A, Chang DZ, et al. Phase II study of RAD001 (everolimus) and depot octreotide (sandostatin LAR) in advanced low grade neuroendocrine carcinoma (LGNET). ASCO Meeting Abstr. 2007; 25: 4503.